非缺血性扩张型心肌病患者心肌纤维化进展及其与死亡和心力衰竭结局的关系
本研究纳入85例接受最佳药物治疗的非缺血性扩张型心肌病患者,间隔中位1.5年行两次心脏磁共振评估左心室射血分数和纤维化。纤维化一旦存在即不消退,18%患者出现纤维化进展,且纤维化进展与全因死亡和心力衰竭相关并发症风险升高独立相关。
要点
- 扩张型心肌病患者心脏磁共振一旦检出替代性纤维化,随访中不会消退或缩小。
- 纤维化进展定义为左心室质量增加>1.8%或新发纤维化,发生率为18%。
- 纤维化进展时左心室射血分数常仅轻微下降(60%病例变化<5%),但全因死亡风险升高。
关键影像表现/征象
- 首次心脏磁共振时,34例(40%)患者存在纤维化,纤维化占左心室质量的中位数为0.0%(四分位距0%至2.6%)。
- 第二次心脏磁共振时,无任何患者出现纤维化消退,70例(82%)患者纤维化表现稳定。
- 15例(18%)患者出现纤维化进展(左心室质量增加>1.8%或新发纤维化),其中46%在首次检查时无纤维化。
诊断标准与关键数值
- 纤维化进展定义为纤维化较基线增加>1.8%左心室质量或出现新发纤维化。
- 纤维化进展与全因死亡风险升高相关(风险比3.4,95%置信区间1.5至7.9,p<0.01)。
- 纤维化进展与心力衰竭相关并发症风险升高相关(风险比3.5,95%置信区间1.5至8.1,p<0.01),校正包括左心室射血分数在内的临床协变量后仍显著。
临床应用与阅片要点
- 对扩张型心肌病患者行心脏磁共振评估时,应报告纤维化的存在、范围及随访变化,因纤维化一旦出现不会消退。
- 纤维化进展可伴随左心室射血分数轻微下降(本研究中60%病例射血分数变化<5%),阅片时不应因射血分数稳定而忽略纤维化进展。
- 纤维化进展与全因死亡和心力衰竭相关并发症风险升高独立相关,提示其可作为风险分层标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of this study was to assess whether the presence and extent of fibrosis changes over time in patients with nonischemic, dilated cardiomyopathy (DCM) receiving optimal medical therapy and the implications of any such changes on left ventricular ejection fraction (LVEF) and clinical outcomes.
BACKGROUND: Myocardial fibrosis on cardiovascular magnetic resonance (CMR) imaging has emerged as important risk marker in patients with DCM.
METHODS: In total, 85 patients (age 56 ± 15 years, 45% women) with DCM underwent serial CMR (median interval 1.5 years) for assessment of LVEF and fibrosis. The primary outcome was all-cause mortality; the secondary outcome was a composite of heart failure hospitalization, aborted sudden cardiac death, left ventricular (LV) assist device implantation, or heart transplant.
RESULTS: On CMR-1, fibrosis (median 0.0 [interquartile range: 0% to 2.6%]) of LV mass was noted in 34 (40%) patients. On CMR-2, regression of fibrosis was not seen in any patient. Fibrosis findings were stable in 70 (82%) patients. Fibrosis progression (increase >1.8% of LV mass or new fibrosis) was seen in 15 patients (18%); 46% of these patients had no fibrosis on CMR-1. Although fibrosis progression was on aggregate associated with adverse LV remodeling and decreasing LVEF (40 ± 7% to 34 ± 10%; p < 0.01), in 60% of these cases the change in LVEF was minimal (<5%). Fibrosis progression was associated with increased hazards for all-cause mortality (hazard ratio: 3.4 [95% confidence interval: 1.5 to 7.9]; p < 0.01) and heart failure-related complications (hazard ratio: 3.5 [95% confidence interval: 1.5 to 8.1]; p < 0.01) after adjustment for clinical covariates including LVEF.
CONCLUSIONS: Once myocardial replacement fibrosis in DCM is present on CMR, it does not regress in size or resolve over time. Progressive fibrosis is often associated with minimal change in LVEF and identifies a high-risk cohort.
引用
- Mandawat A, Chattranukulchai P, Mandawat A, et al. Progression of Myocardial Fibrosis in Nonischemic DCM and Association With Mortality and Heart Failure Outcomes. JACC Cardiovasc Imaging. 2021. PMID: 33454264. doi:10.1016/j.jcmg.2020.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。